Septal Myectomy for Severe Neonatal Hypertrophic Cardiomyopathy Caused by PTPN11 Gene Mutation: A Case Report

Ningning Zhang, Liang Chen and Jing Zhang*

Department of Pediatric Cardiac Surgery, Peking Union Medical College, People's Republic of China

Abstract

Noonan syndrome is rare disease with autosomal dominant genetic pattern. Hypertrophic Obstructive Cardiomyopathy (HOCM) is frequently observed in patients with Noonan syndrome and also represents the major determinant of the patient’s outcome. The reported experience of septal myectomy for infant Noonan syndrome patient with HOCM is very limited worldwide. In present study, we report a Chinese Noonan syndrome patient with severe neonatal hypertrophic obstructive cardiomyopathy, who underwent septal myectomy procedure at 8 months old. This patient received favorable perioperative result and good clinical outcome after 2 years follow-up. This is the earliest report of septal myectomy surgery for Noonan syndrome patient under 1 year of age, which supports that septal myectomy surgery for infant Noonan syndrome patients with HOCM is scalable with substantial benefit for patients.

Introduction

Noonan syndrome is an autosomal dominant disorder characterized by multiple symptoms including facial dysmorphism, bleeding diathesis, proportional short stature and cardiovascular abnormalities often associated with hypertrophic cardiomyopathy [1,2]. This syndrome is known as RASopathies caused by mutations in components of RAS/Mitogen-Activated Protein Kinase (MAPK) pathway such as PTPN11, BRAF, KRAS, SOS1, MAP2K1, and RAF1 etc [3,4]. Hypertrophic Obstructive Cardiomyopathy (HOCM) is frequently observed in patients with Noonan syndrome and also represents the major determinant of the patient’s outcome [2]. It has been reported that Noonan syndrome patients with HOCM have a worse risk profile than the isolated HCM patients [5]. Transaortic ventricular septal myectomy, also known as Morrow procedure, provides excellent outcomes for adult patients with severe HOCM, while its effectiveness in children is poorly reported [6,7]. Moreover, the reported experience of septal myectomy for infant HOCM patient is very limited worldwide. In present study, we report on a Chinese patient with severe Noonan syndrome shown as neonatal hypertrophic obstructive cardiomyopathy, and this patient received good clinical outcome after undergoing septal myectomy procedure at 8 months old. Meanwhile, we performed next-generation sequencing to identify the causative gene defect and confirmed the diagnosis of Noonan syndrome.

Case Presentation

Seven months-old full-term infant weighted 5800 gr was referred to our hospital for the heart murmur. He was estimated as NYHA I and was asymptomatic without respiratory distress, syncope or cyanosis. Her pulse rate was 124/min and rhythmic, blood pressure was 92/55 mmHg, and oxygen saturation was 100% in room air. Lab test showed that the NT-proBNP was 15498 pg/ml and Hb 113g/L. Some of the hepatic and renal function related parameters were abnormal such as aspartate aminotransferase (AST, 80 IU/L), alanine aminotransferase (ALT, 69 IU/L), γ-glutamyltranspeptidase (GGT, 17 IU/L), and total bilirubin (8.9 μmol/L), creatinine (23.9 μmol/L). Echocardiography revealed left ventricular hypertrophy with severe Left Ventricle Outflow Tract (LVOT) obstruction, moderate mitral regurgitation and systolic anterior motion of the mitral valve (SAM sign). Atria septal defect was also observed under Doppler. The LVOT pressure gradient estimated by Doppler flow was 78 mmHg before surgery (Figure 1A).

This patient was subjected to Morrow septal myectomy procedure under general anesthesia with low temperature extracorporeal circulation at her eight months old. The cardiopulmonary
Noonan syndrome and neonatal HOCM. The clinical presentation included facial dysmorphism, cutaneous abnormalities and HCM with LVOT obstruction. These clinical features were suggestive of Noonan syndrome. We performed septal myectomy procedure for this patient, and her LVOT obstruction was relieved with LVOT gradient from 78 mmHg down to 13 mmHg after surgery. This patient also showed good outcome after 3 years follow-up. The treatment of septal myectomy surgery for adult HOCM patient showed excited outcomes after mid- or long-term follow-up in previous studies [10], but its application in pediatric patients were only reported by several centers such as Mayo clinic [6,7,11,12]. A recent study from Germany reported the clinical outcome of septal myectomy for 12 infant HOCM patients under 1 year of age from 1978 to 2015 including 6 Noonan syndrome [13]. They also confirmed this surgery can be performed safely during infancy with favorable perioperative result and long-term clinical outcome at a mean time period of 8.9 years after surgery [13]. The surgery team from Mayo Clinic also reported the outcome of 7 septal myectomy surgeries in patients with Noonan syndrome from 1999 to 2015, which also proved a reasonable and acceptable early outcome for these patients [14]. Although there were several reports on the surgery for Noonan syndrome, the sample size are all so small that this surgery is still under exploration. Our group is the first team to perform septal myectomy surgery for infant patients in China, and this is also the first case reported from Chinese hospital. And it is worthy to be confirmed that the septal myectomy surgery for Noonan syndrome patients with HOCM is scalable with substantial benefit for patients.

**References**

1. Burch M, Sharland M, Shinebourne E, Smith G, Patton M, McKenna W. Cardiologic abnormalities in Noonan syndrome: phenotypic diagnosis and echocardiographic assessment of 118 patients. J Am Coll Cardiol. 1993;22(4):1189-92.

2. Calcagni G, Adorisi R, Martinelli S, Grueter G, Baban A, Versacci P, et al. Clinical Presentation and Natural History of Hypertrophic Cardiomyopathy in RASopathies. Heart Fail Clin. 2018;14(2):225-35.

3. Liao J, Mehta L. Molecular Genetics of Noonan Syndrome and RASopathies. Pediatr Endocrinol Rev. 2019;16(Suppl 2):435-46.

4. Li X, Yao R, Tan X, Li N, Ding Y, Li J, et al. Molecular and phenotypic spectrum of Noonan syndrome in Chinese patients. Clin Genet. 2019.

5. Prendiville TW, Gauvreau K, Tworog-Dube E, Patkin L, Kucherlapati RS, Roberts AE, et al. Cardiovascular disease in Noonan syndrome. Arch Dis Child. 2014;99(7):629-34.

6. Borisov KV, Bockeira LA, Sinyov AF. Surgical treatment of hypertrophic obstructive cardiomyopathy in pediatric patients with severe hypertrophy. Artif Organs. 2008;32(11):856-63.
7. Altarabsheh SE, Dearani JA, Burkhart HM, Schaff HV, Deo SV, Eidem BW, et al. Outcome of septal myectomy for obstructive hypertrophic cardiomyopathy in children and young adults. Ann Thorac Surg. 2013;95(2):663-9.

8. Takahashi K, Kogaki S, Karotobi S, Nasuno S, Ohta M, Okabe H, et al. A novel mutation in the PTPN11 gene in a patient with Noonan syndrome and rapidly progressive hypertrophic cardiomyopathy. Eur J Pediatr. 2005;164(8):497-500.

9. Digilio MC, Sarkozy A, Pacileo G, Limongelli G, Marino B, Dallapiccola B. PTPN11 gene mutations: linking the Gln510Glu mutation to the "LEOPARD syndrome phenotype". Eur J Pediatr. 2006;165(11):803-5.

10. Nishimura RA, Seggewiss H, Schaff HV. Hypertrophic Obstructive Cardiomyopathy: Surgical Myectomy and Septal Ablation. Circ Res. 2017;121(7):771-83.

11. Dearani JA, Danielson GK. Septal myectomy for obstructive hypertrophic cardiomyopathy. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2005:86-91.

12. Minakata K, Dearani JA, O’Leary PW, Danielson GK. Septal myectomy for obstructive hypertrophic cardiomyopathy in pediatric patients: early and late results. Ann Thorac Surg. 2005;80(4):1424-9. Discussion 9-30.

13. Schleia hauf J, Cleuziou J, Pabst von Ohain J. Clinical long-term outcome of septal myectomy for obstructive hypertrophic cardiomyopathy in infants. Eur J Cardiothorac Surg. 2018;53(3):538-44.

14. Hemmati P, Dearani JA, Daly RC, King KS, Ammash NM, Cetta F, et al. Early Outcomes of Cardiac Surgery in Patients with Noonan Syndrome. Semin Thorac Cardiovasc Surg. 2018.